Viva Biotech buys 80% share of Langhua Pharma | Healthcare Asia Magazine
, China

Viva Biotech buys 80% share of Langhua Pharma

The company expects to deliver more comprehensive end-to-end services through this acquisition.

Viva Biotech has entered into a share purchase agreement, pursuant to which, they will acquire 80% of equity interest in Langhua Pharmaceutical, with a price of $368.5m, the company said in a press release. Through this acquisition, Viva Biotech will benefit from an established contract development & manufacturing organisation (CDMO), the company claimed.

As Langhua Pharmaceutical focuses mostly on APIs, intermediates production, and CDMO projects, the acquisition is claimed to enable Viva Biotech to exploit from the future high-speed growth service demand of portfolio companies under EFS mode, and expand the portfolio of potential incubation projects.

An extraordinary general meeting (EGM) is planned to be held for the shareholders to consider and approve the acquisition, the press release added.
 

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!